News

European regulators OK Alzheimer's treatment Leqembi after initial doubts
European regulators have finally approved the Alzheimer's treatment Leqembi after an advisory committee initially rejected the drug last summer.
Biogen reports EC grants marketing authorization for Leqembi
The European Commission has granted the amyloid-beta monoclonal antibody Leqembi Marketing Authorization in the European Union. Lecanemab is ...
Biogen (BIIB) Receives a Hold from Jefferies
Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...
Reuters3d
EU authorizes Eisai-Biogen's drug for early Alzheimer's treatment
April 15 (Reuters) - The European Commission on Tuesday authorized the use of Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab drug to treat some patients with mild cognitive ...
Biogen Inc. stock underperforms Wednesday when compared to competitors
Shares of Biogen Inc. BIIB shed 1.44% to $115.29 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...